. Patients with methylated MGMT gene who were trea
Post# of 155128
(Total Views: 595)
Posted On: 12/17/2023 6:53:50 AM
Quote:
. Patients with methylated MGMT gene who were treated with the vaccine survived 30.2 months on average from randomization in the trial (33 months from surgery) compared to 21.3 months for the control group.
Very interesting, I took a look at what the methylated MGMT gene does. It reduces the amount of DNA repair in glioblastoma even without the use of DCVAX-L. DCVAX-L most likely works better with it because of an improved immune response.
Leronlimab has an improved immune response but more importantly it has it's own method of breaking DNA repair through downregulation of the PI3K/Akt pathway. Since this does not involve the super-methylated MGMT gene it is an additional benefit whether the patient has that gene mutation or not.
This is how much leronlimab can affect that DNA repair.
Quote:
CCR5 inhibitor addition increased the GR50 of doxorubicin-mediated cell killing by up to 4-fold.
https://aacrjournals.org/cancerres/article/78...ast-Cancer
(18)
(0)